MDACC Study No:2012-0740 ( NCT No: NCT01585688)
Title:A Phase I/II Study of Immunotherapy with hLL1-DOX in Patients
with Non-Hodgkin’s Lymphoma (NHL) and Chronic Lymphocytic
Leukemia (CLL)
Principal Investigator:Felipe Samaniego
Treatment Agent:hLL1-DOX
Study Status:Open
Study Description:The goal of the Phase I part of this clinical research study is to find the
highest tolerable dose of hLL1-DOX that can be given to patients with NHL or

The goal of Phase II is to learn if hLL1-DOX can help control NHL or CLL. The
safety of this drug will also be studied.

hLL1-DOX is made up of hLL1 (an antibody - a substance that can locate and bind
to foreign objects [such as cancer cells] wherever they are in the body) and
doxorubicin (a drug designed to stop the growth of cancer cells). This
combination may cause the cancer cells to die.
Hide details for General InformationGeneral Information

Disease Group:Leukemia; Lymphoma
Phase of Study:Phase I/Phase II
Treatment Agents:hLL1-DOX
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Immunomedics, Inc.
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Felipe Samaniego
For Clinical Trial Enrollment:713-792-2860
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults